Epidermal growth factor receptor blockers for the treatment of ovarian cancer-Reference-Cited by-同舟云学术

Epidermal growth factor receptor blockers for the treatment of ovarian cancer

Published:2018-10-15 Issue: Volume: Page:
ISSN:1465-1858
Container-title:Cochrane Database of Systematic Reviews
language:en
Short-container-title:

Author:

Morrison Jo¹,Thoma Clemens²,Goodall Richard J³,Lyons Thomas J⁴,Gaitskell Kezia⁵,Wiggans Alison J⁶,Bryant Andrew⁷

Affiliation:

1. Musgrove Park Hospital; Department of Gynaecological Oncology; Taunton and Somerset NHS Foundation Trust Taunton Somerset UK TA1 5DA

2. Springer Nature; London UK

3. Imperial College London; Kensington London UK SW7 2AZ

4. University of Bristol; School of Medical Sciences; 38 Kings Parade Avenue Bristol UK BS8 2RB

5. University of Oxford; Cancer Epidemiology Unit, Nuffield Department of Population Health; Richard Doll Building Roosevelt Drive Oxford UK OX3 7LF

6. Musgrove Park Hospital; Department of Obstetrics and Gynaecology; Taunton and Somerset NHS Foundation Trust Taunton Somerset UK TA1 5DA

7. Newcastle University; Institute of Health & Society; Medical School New Build Richardson Road Newcastle upon Tyne UK NE2 4AX

Publisher

Wiley

Subject

Pharmacology (medical)

Link

https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD007927.pub4/epdf/full

Reference125 articles.

1. Panitumumab in platinum-sensitive epithelial ovarian cancer patients with KRAS wild-type: the PROVE-study, a phase II randomized multicenter study of the North-Eastern German Society of Gynaecologic Oncology;Chekerov;Journal of Clinical Oncology,2017

2. WiSP Wissenschaftlicher Service Pharma GmbH PROVE: A Randomized Phase II Trial of Standard Carboplatin-based Chemotherapy With or Without Panitumumab in Platinum-sensitive Recurrent Ovarian Cancer ClinicalTrials.gov May 2011

3. Coleman RL Moon J Sood A Branham D Delmore JE Bonebrake AJ Randomized phase II study of docetaxel plus vandetanib (D+V) versus docetaxel followed by vandetanib (D-V) in patients with persistent or recurrent epithelial ovarian, fallopian tube, or primary peritoneal carcinoma (OC): SWOG S0904 European Journal of Cancer 2014 1638 48

4. Southwest Oncology Group National Cancer Institute Docetaxel with or without vandetanib in treating patients with persistent or recurrent ovarian epithelial cancer, fallopian tube cancer, or primary peritoneal cancer (NCT00872989) Protocol registered at ClinicalTrials.gov on 31 March 2009

5. A randomized phase II study evaluating the combination of carboplatin-based chemotherapy with pertuzumab versus carboplatin-based therapy alone in patients with relapsed, platinum sensitive ovarian cancer;Kaye;Journal of Clinical Oncology,2008

Cited by 19 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Unveiling the Immunogenicity of Ovarian Tumors as the Crucial Catalyst for Therapeutic Success;Cancers;2023-12-02

2. Development and Perspectives: Multifunctional Nucleic Acid Nanomedicines for Treatment of Gynecological Cancers;Small;2023-07-30

3. EGFR-selective activation of CD27 co-stimulatory signaling by a bispecific antibody enhances anti-tumor activity of T cells;Frontiers in Immunology;2023-07-20

4. Angiogenesis inhibitors for the treatment of epithelial ovarian cancer;Cochrane Database of Systematic Reviews;2023-04-18

5. Targeting receptor tyrosine kinases in ovarian cancer: Genomic dysregulation, clinical evaluation of inhibitors, and potential for combinatorial therapies;Molecular Therapy - Oncolytics;2023-03